A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

Sequential, ascending-dose study with up to four cohorts; each participant receives a 5-day BID course of cohort-specified oral ketamine and a 5-day course of matched placebo in randomised, double-blind crossover order with 2-week safety follow-up after each period.

Primary assessments include safety and tolerability (AEs, vitals, physical exam, concomitant medications); exploratory efficacy via physician and caregiver questionnaires and continuous wearable at-home biosensor data.